Last updated on November 2019

A Study to Test Safety Tolerability and the Way the Body Absorbs Distributes and Gets Rid of a Study Drug Called MOR106 in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis

---

Brief description of study

The clinical study consists of three parts:

• Part 1 with healthy volunteers.
• Part 2 and Part 3 including subjects with moderate to severe atopic dermatitis (a skin disease).

For Part 1 the main goal of the study is to compare the safety, tolerability, and exposure of administration of the test drug via an injection in a skin layer just under the surface (subcutaneous), to administration of the test drug into the vein (intravenous).

For Part 2 and Part 3 the main goal of the study is to assess the safety and tolerability of administration of the test drug via an injection in a skin layer just under the surface (subcutaneous) during 12 weeks of treatment.